Latest Insider Transactions at Collegium Pharmaceutical, Inc (COLL)
This section provides a real-time view of insider transactions for Collegium Pharmaceutical, Inc (COLL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of COLLEGIUM PHARMACEUTICAL, INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of COLLEGIUM PHARMACEUTICAL, INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,593
-15.13%
|
$345,348
$36.62 P/Share
|
|
Sep 06
2024
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
977
-0.81%
|
$36,149
$37.46 P/Share
|
|
Sep 05
2024
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
19,248
-7.02%
|
$731,424
$38.66 P/Share
|
|
Jun 03
2024
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
25,000
-7.64%
|
$800,000
$32.89 P/Share
|
|
May 28
2024
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,710
-13.09%
|
$670,140
$34.21 P/Share
|
|
May 24
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
56,807
-34.91%
|
$1,874,631
$33.98 P/Share
|
|
May 24
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,791
+12.76%
|
$570,984
$24.03 P/Share
|
|
May 23
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
51,209
-26.93%
|
$1,689,897
$33.82 P/Share
|
|
May 23
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,209
+21.22%
|
$1,229,016
$24.03 P/Share
|
|
May 16
2024
|
Garen G Bohlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.79%
|
-
|
|
May 16
2024
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+14.46%
|
-
|
|
May 16
2024
|
Rita J. Balice Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+14.2%
|
-
|
|
May 16
2024
|
John A. Fallon Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.3%
|
-
|
|
May 16
2024
|
John Gordon Freund Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.79%
|
-
|
|
May 16
2024
|
Neil F. Mc Farlane Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+13.48%
|
-
|
|
May 16
2024
|
Gwen A Melincoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.79%
|
-
|
|
May 16
2024
|
Gino Santini Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+9.23%
|
-
|
|
May 14
2024
|
Garen G Bohlin Director |
SELL
Open market or private sale
|
Direct |
28,985
-39.3%
|
$927,520
$32.3 P/Share
|
|
May 14
2024
|
Garen G Bohlin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
28,985
+28.21%
|
$144,925
$5.73 P/Share
|
|
Feb 29
2024
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
995
-1.54%
|
$35,820
$36.76 P/Share
|
|
Feb 26
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-3.37%
|
$360,000
$36.77 P/Share
|
|
Feb 12
2024
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,199
-2.39%
|
$105,567
$33.7 P/Share
|
|
Feb 12
2024
|
Thomas B Smith EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,423
+19.62%
|
-
|
|
Feb 12
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,690
-8.66%
|
$979,770
$33.7 P/Share
|
|
Feb 12
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,286
+17.31%
|
-
|
|
Feb 12
2024
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,321
-7.72%
|
$868,593
$33.7 P/Share
|
|
Feb 12
2024
|
Colleen Tupper EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,456
+18.3%
|
-
|
|
Feb 12
2024
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
128,867
-11.87%
|
$4,252,611
$33.7 P/Share
|
|
Feb 12
2024
|
Joseph Ciaffoni President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
298,734
+23.53%
|
-
|
|
Feb 12
2024
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
31,756
-8.42%
|
$1,047,948
$33.7 P/Share
|
|
Feb 12
2024
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
76,647
+17.76%
|
-
|
|
Jan 16
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
23,560
-17.47%
|
$753,920
$32.28 P/Share
|
|
Dec 21
2023
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
4,357
-1.56%
|
$130,710
$30.38 P/Share
|
|
Dec 21
2023
|
Joseph Ciaffoni President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,357
+1.54%
|
$91,497
$21.34 P/Share
|
|
Dec 20
2023
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
26,454
-8.78%
|
$793,620
$30.4 P/Share
|
|
Dec 20
2023
|
Joseph Ciaffoni President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,454
+8.07%
|
$555,534
$21.34 P/Share
|
|
Dec 19
2023
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
14,516
-5.01%
|
$435,480
$30.03 P/Share
|
|
Dec 19
2023
|
Joseph Ciaffoni President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,516
+4.77%
|
$304,836
$21.34 P/Share
|
|
Dec 18
2023
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
27,798
-9.18%
|
$833,940
$30.04 P/Share
|
|
Dec 18
2023
|
Joseph Ciaffoni President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,798
+8.41%
|
$583,758
$21.34 P/Share
|
|
Nov 27
2023
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
25,600
-17.64%
|
$640,000
$25.78 P/Share
|
|
Nov 27
2023
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
25,600
+15.0%
|
$384,000
$15.9 P/Share
|
|
Jun 26
2023
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
17,984
-6.61%
|
$395,648
$22.09 P/Share
|
|
Jun 02
2023
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
31,272
-5.12%
|
$656,712
$21.92 P/Share
|
|
Jun 01
2023
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
31,272
-9.26%
|
$687,984
$22.09 P/Share
|
|
May 31
2023
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
31,272
-8.48%
|
$656,712
$21.87 P/Share
|
|
May 30
2023
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
31,271
-7.82%
|
$656,691
$21.9 P/Share
|
|
May 18
2023
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,792
+20.57%
|
-
|
|
May 18
2023
|
Neil F. Mc Farlane Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,792
+19.03%
|
-
|
|
May 18
2023
|
Rita J. Balice Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,792
+20.15%
|
-
|